Literature DB >> 2005071

Neuroleptic malignant syndrome associated with clozapine use.

E S Anderson1, P S Powers.   

Abstract

Clozapine, an atypical antipsychotic drug, is indicated for severely ill schizophrenic patients refractory to treatment with conventional neuroleptics. One advertised advantage of clozapine is the absence of associated neuroleptic malignant syndrome (NMS). On the basis of a clinical case, the authors question this claim. They are concerned that this potentially fatal condition may be misdiagnosed if physicians are not aware of possible NMS associated with the use of clozapine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005071

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

2.  Rechallenging clozapine after neuroleptic malignant syndrome.

Authors:  Emaya Anbalagan; Muaid Ithman; John Lauriello
Journal:  Psychiatr Q       Date:  2014-09

Review 3.  When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

Authors:  Peter Manu; Deepak Sarpal; Owen Muir; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2011-11-22       Impact factor: 4.939

Review 4.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 5.  Recent developments in the management of psychosis.

Authors:  M J Hoes
Journal:  Pharm World Sci       Date:  1998-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.